Welcome to our dedicated page for Arcutis Biotherapeutics SEC filings (Ticker: ARQT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) provides access to the company’s official U.S. regulatory disclosures as a commercial-stage biopharmaceutical and medical dermatology issuer. These documents, filed with the Securities and Exchange Commission, give detailed insight into Arcutis’ financial performance, governance, and progress in developing and commercializing therapies for immune-mediated dermatological diseases and conditions.
Key filings include annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe product revenue from the ZORYVE (roflumilast) franchise, research and development expenses related to atopic dermatitis, plaque psoriasis, seborrheic dermatitis, and pipeline programs, as well as selling, general, and administrative costs tied to commercialization. These reports also summarize risk factors, intellectual property, and other information relevant to Arcutis’ pharmaceutical preparation manufacturing activities.
Current reports on Form 8-K document material events such as quarterly and year-to-date financial results, strategic updates, and changes in the composition of the board of directors. For example, recent 8-K filings describe the release of financial results for specific quarters and the retirement and appointment of directors, including details of compensation arrangements and consulting agreements. Such filings help investors track governance developments and corporate actions in real time.
Investors interested in executive and director compensation, equity awards, and governance policies can review proxy statements and related exhibits, while those monitoring capital structure and financing activities can examine notes in periodic reports and any registration statements or prospectus supplements that may be filed. Filings also confirm that Arcutis’ common stock is registered under Section 12(b) of the Exchange Act and listed on The Nasdaq Global Select Market under the symbol ARQT.
On this page, Stock Titan pairs Arcutis’ raw SEC filings with AI-powered summaries that highlight key points from lengthy documents, such as revenue trends for ZORYVE products, major R&D milestones, and notable risk factor updates. Users can quickly scan AI-generated overviews of Forms 10-K and 10-Q, then drill into the full text for deeper analysis. Real-time ingestion from EDGAR ensures that new 8-Ks, periodic reports, and exhibits appear promptly, while structured views of ownership and transaction data make it easier to follow equity awards and other reportable items disclosed in Arcutis’ filings.
Arcutis Biotherapeutics (ARQT) filed a Form 4 reporting insider stock sales. Executive Vice President and Chief Medical Officer Patrick Burnett reported selling 2,607 shares of common stock on 11/03/2025 at a weighted average price of $24.7124 and 15 shares at $25.4. He also sold 3,864 shares on 11/05/2025 at a weighted average price of $23.7172. Following these transactions, he beneficially owned 98,325 shares directly.
The 11/03/2025 sale was made to cover tax withholding obligations tied to vesting Restricted Stock Units. The 11/05/2025 transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024, with a plan end date of February 27, 2026.
Arcutis Biotherapeutics (ARQT) director Howard G. Welgus sold 10,000 shares of common stock on 11/03/2025 under a Rule 10b5-1 trading plan. The weighted average sale price was $25.2669, with individual trades ranging from $25.10 to $25.4298.
Following the sale, he beneficially owned 89,744 shares, held directly. The 10b5-1 plan was adopted on March 11, 2025 and has an end date of May 29, 2026.
Arcutis Biotherapeutics (ARQT) reported an insider transaction by its SVP Chief Financial Officer. On 11/03/2025, the officer sold 88 shares of common stock at a weighted average price of $24.7185, as noted in the filing.
The footnote states the sale was made to cover tax withholding upon the vesting of Restricted Stock Units. Following the transaction, the officer beneficially owned 64,927 shares directly. The trades occurred in multiple lots between $24.435 and $25.31.
Arcutis Biotherapeutics (ARQT) reported insider activity by its President, Chief Executive Officer, and Director. On November 3, 2025, the reporting person sold 11,547 shares of common stock to cover tax withholding obligations tied to the vesting of restricted stock units.
The sales occurred at weighted-average prices of $24.7122 and $25.3991. Following these transactions, the reporting person directly owned 794,893 shares. Additional indirect holdings were reported, including 124,956 shares held by a trust and 57,358 shares held by an LLC, along with other trust-held positions.
Arcutis Biotherapeutics (ARQT) insider transaction: An officer sold shares on 11/03/2025 primarily to cover tax withholding tied to RSU vesting. The filing reports two sales: 7,165 shares at a weighted average price of $24.7123 and 43 shares at a weighted average price of $25.3985. Following these transactions, the reporting person directly held 154,026 shares. The reporting person’s title is SVP General Counsel and Corporate Secretary.
Arcutis Biotherapeutics (ARQT): President and CEO Todd Franklin Watanabe reported selling 40,000 shares of common stock on 10/28/2025 at a weighted average price of $25.0258, with individual trades ranging from $25.00 to $25.1691. The sale was made under a Rule 10b5-1 trading plan adopted on June 3, 2025, with a plan end date of September 30, 2026.
Following the transaction, he beneficially owns 806,440 shares directly. Indirect holdings include 25,410 shares by The John Franklin Watanabe Trust, 25,410 shares by The Anderson Prest Watanabe Irrevocable Trust, 57,358 shares by Watanabe Ventures, LLC, and 124,956 shares by The Watanabe 2016 Irrevocable Trust.
Arcutis Biotherapeutics (ARQT): President and CEO Todd Franklin Watanabe reported selling 40,000 shares of common stock on 10/28/2025 at a weighted average price of $25.0258, with individual trades ranging from $25.00 to $25.1691. The sale was made under a Rule 10b5-1 trading plan adopted on June 3, 2025, with a plan end date of September 30, 2026.
Following the transaction, he beneficially owns 806,440 shares directly. Indirect holdings include 25,410 shares by The John Franklin Watanabe Trust, 25,410 shares by The Anderson Prest Watanabe Irrevocable Trust, 57,358 shares by Watanabe Ventures, LLC, and 124,956 shares by The Watanabe 2016 Irrevocable Trust.
Arcutis Biotherapeutics (ARQT) reported a profitable Q3 2025 driven by strong product sales. Total revenue reached $99,219,000, more than doubling from $44,755,000 a year ago, and operating income was $8,526,000. Net income was $7,410,000, a sharp turnaround from a net loss of $41,537,000 in Q3 2024. Product revenue was led by ZORYVE foam at $49,781,000, ZORYVE cream 0.3% at $30,491,000, and ZORYVE cream 0.15% at $18,947,000. Cost of sales was $8,685,000.
For the first nine months, revenue was $246,569,000 versus $125,182,000 in 2024, with a net loss of $33,536,000. Cash, cash equivalents, restricted cash, and marketable securities were $191,068,000 as of September 30, 2025. The company reported long-term debt of $100,000,000 and interest expense of $3,071,000 for the quarter. Shares outstanding were 122,492,192 as of October 22, 2025. Management notes recent approvals across multiple ZORYVE formulations in the U.S. and Canada, and recorded a $10,000,000 milestone payment to AstraZeneca tied to sales, increasing intangible assets amortized through cost of sales.
Arcutis Biotherapeutics, Inc. filed a current report to note that it issued a press release on October 28, 2025 outlining its strategy for driving sustainable growth and reporting financial results for the quarter ended September 30, 2025. The company furnished the full press release as Exhibit 99.1, rather than including detailed financial figures in the report itself. The filing clarifies that the press release is being provided for informational purposes and is not considered filed for liability purposes under the securities laws unless specifically incorporated by reference in a future filing.
Jennison Associates LLC reported beneficial ownership of 12,254,119 shares of Arcutis Biotherapeutics, Inc. common stock, representing 10.2% of the class as of the event date 09/30/2025. The filing is a Schedule 13G (Amendment No. 3), indicating passive investment reporting by an investment adviser registered in Delaware. Jennison discloses sole voting power for all 12,254,119 shares and shared dispositive power for the same amount, while claiming no sole dispositive power. The statement certifies the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing is signed by a compliance officer on 10/06/2025.
Larry Todd Edwards, EVP Chief Commercial Officer of Arcutis Biotherapeutics (ARQT), reported sales of 4,504 shares of common stock on 10/02/2025 to cover tax withholding arising from the vesting of Restricted Stock Units granted 2/22/2024. The sales were reported as two grouped transactions: 4,207 shares at a weighted average price of $19.9885 and 297 shares at a weighted average price of $20.7801. Following the transactions, beneficial ownership is reported at 179,324 shares. The filing also notes a purchase of 724 shares under the Employee Stock Purchase Plan on 5/31/2025. The seller certified the weighted‑average price ranges and offered to provide per‑trade details on request.